Protection and regeneration of nigral dopaminergic neurons by neurturin or GDNF in a partial lesion model of Parkinson's disease after administration into the striatum or the lateral ventricle.
about
Gene therapy in Parkinson's disease: rationale and current statusA Compendium of Preparation and Application of Stem Cells in Parkinson's Disease: Current Status and Future ProspectsParkinson's disease: gene therapiesParkinson's disease gene therapy: success by design meets failure by efficacyActivin A protects midbrain neurons in the 6-hydroxydopamine mouse model of Parkinson's diseaseEnhanced delivery and bioactivity of the neurturin neurotrophic factor through focused ultrasound-mediated blood--brain barrier opening in vivo.Delayed infusion of GDNF promotes recovery of motor function in the partial lesion model of Parkinson's disease.GDNF reverses priming for dyskinesia in MPTP-treated, L-DOPA-primed common marmosets.Comparison of unilateral and bilateral intrastriatal 6-hydroxydopamine-induced axon terminal lesions: evidence for interhemispheric functional coupling of the two nigrostriatal pathways.Therapeutic efficacy of AAV8-mediated intrastriatal delivery of human cerebral dopamine neurotrophic factor in 6-OHDA-induced parkinsonian rat models with different disease progression.Neurturin effects on nigrostriatal dopamine release and content: comparison with GDNFGlial cell line-derived neurotrophic factor protects midbrain dopaminergic neurons against lipopolysaccharide neurotoxicity.Neurturin protects against 6-hydroxydopamine-induced reductions in evoked dopamine overflow in rat striatum.Gene therapy for Parkinson's disease: review and update.Prospects for the treatment of Parkinson's disease using neurotrophic factors.Advances in gene therapy for movement disorders.Expression of trefoil factor 1 in the developing and adult rat ventral mesencephalon.Huntington's Disease: From Mutant Huntingtin Protein to Neurotrophic Factor Therapy.Neurorestoration.Striatal pleiotrophin overexpression provides functional and morphological neuroprotection in the 6-hydroxydopamine model.NTS-Polyplex: a potential nanocarrier for neurotrophic therapy of Parkinson's diseaseDopaminergic regeneration by neurturin-overexpressing c17.2 neural stem cells in a rat model of Parkinson's disease.Neurotrophic factors in neurodegeneration.IGF-1 protects dopamine neurons against oxidative stress: association with changes in phosphokinases.Treatment of Parkinson's disease with trophic factors.Intraputamenal infusion of exogenous neurturin protein restores motor and dopaminergic function in the globus pallidus of MPTP-lesioned rhesus monkeysGDNF therapy for Parkinson's disease.Trophic factors therapy in Parkinson's disease.Comparative study of the neurotrophic effects elicited by VEGF-B and GDNF in preclinical in vivo models of Parkinson's disease.Delayed transplantation of precursor cell-derived astrocytes provides multiple benefits in a rat model of Parkinsons.Use of growth factors for the treatment of Parkinson's disease.Gene therapy: a viable therapeutic strategy for Parkinson's disease?Gene therapy for Parkinson's disease: where are we now and where are we going?An update on gene therapy in Parkinson's disease.Trophic factor gene therapy for Parkinson's disease.Advances in non-dopaminergic treatments for Parkinson's diseaseHuman olfactory bulb neural stem cells mitigate movement disorders in a rat model of Parkinson's disease.Viral vector delivery of neurotrophic factors for Parkinson's disease therapy.Intranasal gene delivery for treating Parkinson's disease: overcoming the blood-brain barrier.Morphological Changes in a Severe Model of Parkinson's Disease and Its Suitability to Test the Therapeutic Effects of Microencapsulated Neurotrophic Factors.
P2860
Q22241423-D04C438E-28E1-4A10-8A60-FA34A581D9E5Q26746033-70BDFA65-63C2-472C-B925-10C9695B149FQ26824184-C4C0D249-7F59-4D72-BE29-5E15D49EB9DBQ26851325-67DCF7A0-6FA5-47A0-95C1-CF9EA6E54B33Q27309140-294C2272-E1DC-4019-831D-EE449A780373Q30387126-CA66A33D-F919-4FC9-85F9-7B152971277EQ30666545-0F7917C1-C135-49DF-9EF8-C0785DF1559AQ31900813-17FC55B5-29CF-4784-A42F-601AF61FB7FFQ32160990-02898EBC-BA8A-4E40-9795-2634DEB67D9DQ33807060-E14BF87B-BF6C-40A7-A313-5357BBE67C63Q33812955-56B5BEB3-7073-4F7F-AF2C-6E28EBB3765EQ34077007-C9BE0F66-D28E-4877-ACAC-562EEDABA2F4Q34108184-DB79EAF6-F815-4983-A817-2A7AB49F166BQ34119491-3AB5D9A7-9B41-4055-B731-974CB8D35951Q34515354-32CAFBEF-B9E4-457A-B349-1303A1453373Q34656049-8BD1B57A-618B-4DDE-BE76-575F363FB40CQ35014745-7E74C1E9-80C9-489B-B571-2D729681AC77Q35158643-4B2E10A4-092D-42D8-810B-FD805946D298Q35631869-EE1213E8-1DE4-4E4F-AB8A-7AFC6F4FE267Q35802100-164EDC14-EA80-448D-B98D-7B7A7AF073AAQ36089698-6C292EB4-EBF8-409E-903C-9F74BFD005E4Q36151216-3597DA79-0C39-4D5D-A45F-209E1EFB6E6DQ36654492-2C703C0D-73AC-4F76-9798-3ADE4D7F8014Q36971278-D15EFF52-C457-4DC7-B4AF-978BE3DE3EC7Q37131259-048F7712-030C-4036-BE6E-E4249181488DQ37187908-8958B1C1-9450-4FCD-8690-16F9FB4AAB7EQ37203371-FE884689-4006-4D59-BA8C-953047AB7E42Q37574424-4CA55990-7F99-47F0-81B1-C08E718B5F4AQ37582397-A88018E9-CDA9-4F69-9B4B-DB516C7018EBQ37710820-2D6B2CFE-E4CD-49D2-9014-DFAEC6424F0AQ37762259-20FCD27F-2CAA-4472-AEBF-EF9A5E21C89BQ37801855-B746977D-B88B-4881-9A80-79F1CC101F6DQ37810994-BDFE952E-3405-4A19-BB41-E07824FD8B54Q37863587-7EB33DD5-871A-4DFC-94F3-626CF35167B3Q38079792-D016D6E0-800B-4195-8079-677688615AAEQ38218083-F97101F8-AFD0-403D-92BD-5281B5FBF12FQ38302028-A08427F9-FD33-45E7-94E7-1640D28BFC5CQ38495722-1207BF28-D54D-4433-82FB-52EEFCD21EA9Q38569775-C16414D1-856E-4618-BD09-813A0975E416Q38731068-D46E3788-BF9D-4914-BCC7-491E76E6739D
P2860
Protection and regeneration of nigral dopaminergic neurons by neurturin or GDNF in a partial lesion model of Parkinson's disease after administration into the striatum or the lateral ventricle.
description
1999 nî lūn-bûn
@nan
1999年の論文
@ja
1999年論文
@yue
1999年論文
@zh-hant
1999年論文
@zh-hk
1999年論文
@zh-mo
1999年論文
@zh-tw
1999年论文
@wuu
1999年论文
@zh
1999年论文
@zh-cn
name
Protection and regeneration of ...... atum or the lateral ventricle.
@en
type
label
Protection and regeneration of ...... atum or the lateral ventricle.
@en
prefLabel
Protection and regeneration of ...... atum or the lateral ventricle.
@en
P2093
P2860
P1476
Protection and regeneration of ...... atum or the lateral ventricle.
@en
P2093
P2860
P304
P356
10.1046/J.1460-9568.1999.00566.X
P407
P577
1999-05-01T00:00:00Z